Causes, Clinical Features, and Outcomes From a Prospective Study of Drug-Induced Liver Injury in the United States

2008/09/18 by Naga Chalasani, Robert J. Fontana, Herbert L. Bonkovsky +7 · 31 citations
Pharmacology, Toxicology and Pharmaceutics · Medicine · #Drug-Induced Hepatotoxicity and Protection #Poisoning and overdose treatments #Chemotherapy-induced organ toxicity mitigation

paper · pdf · doi:10.1053/j.gastro.2008.09.011

Citations

• Drug-induced liver injury: Hy’s rule revisited
• Drug-Induced Liver Injury: An Analysis of 461 Incidences Submitted to the Spanish Registry Over a 10-Year Period
• Results of a Prospective Study of Acute Liver Failure at 17 Tertiary Care Centers in the United States

Cited by

• Features and Outcomes of 899 Patients With Drug-Induced Liver Injury: The DILIN Prospective Study
• Use of Hy's Law and a New Composite Algorithm to Predict Acute Liver Failure in Patients With Drug-Induced Liver Injury
• Beyond Hy's Law: Importance of Markedly Elevated Aminotransferases without Hyperbilirubinemia
• Pharmacogenomics of antibacterial and antiviral therapies: Clinical actionability, evidence gaps, and future directions
• Clinical and Genetic Associations in Cephalosporin‐Induced Liver Injury: Insights From the Drug‐Induced Liver Injury Network
• Unraveling chemotherapy-evoked hepatic dysfunction: a deep dive into cyclophosphamide-related liver injury
• Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct. [europepmc]
• Epidemiology of idiosyncratic drug-induced liver injury. [europepmc]
• Risk factors for idiosyncratic drug-induced liver injury. [europepmc]
• Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method. [europepmc]
• Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop. [europepmc]
• Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. [europepmc]
• Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. [europepmc]
• Hepatic safety of antibiotics used in primary care. [europepmc]
• Acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury. [europepmc]
• Drug-induced Liver Injury. [europepmc]
• Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations. [europepmc]
• Drug-induced acute liver failure. [europepmc]
• Pathogenesis of idiosyncratic drug-induced liver injury and clinical perspectives. [europepmc]
• Idiosyncratic drug-induced liver injury is associated with substantial morbidity and mortality within 6 months from onset. [europepmc]
• Spectrum of statin hepatotoxicity: experience of the drug-induced liver injury network. [europepmc]
• Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network. [europepmc]
• Features and Outcomes of 899 Patients With Drug-Induced Liver Injury: The DILIN Prospective Study. [europepmc]
• RUCAM in Drug and Herb Induced Liver Injury: The Update. [europepmc]
• Hepatotoxicity by Drugs: The Most Common Implicated Agents. [europepmc]
• Amoxicillin-Clavulanate-Induced Liver Injury. [europepmc]
• Definition and risk factors for chronicity following acute idiosyncratic drug-induced liver injury. [europepmc]
• Minocycline hepatotoxicity: Clinical characterization and identification of HLA-B∗35:02 as a risk factor. [europepmc]
• CSH guidelines for the diagnosis and treatment of drug-induced liver injury. [europepmc]
• Pharmacokinetics and safety of aztreonam/avibactam for the treatment of complicated intra-abdominal infections in hospitalized adults: results from the REJUVENATE study. [europepmc]
• Knowledge Mapping of Drug-Induced Liver Injury: A Scientometric Investigation (2010-2019). [europepmc]